Compare Bank of Nova Scotia (BNS) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Enveric Biosciences Inc — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $107.95B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Bank of Nova Scotia is far larger — about 17411.3× Enveric Biosciences Inc's market cap, and Bank of Nova Scotia pays a 3.65% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| BNS | ENVB | |
|---|---|---|
Market Cap | $107.95B | $6.20M |
Sector | Financials | Health |
52-Week High | $90.29 | $17.40 |
52-Week Low | $56.06 | $1.27 |
Dividend Yield | 3.65% | — |
Enterprise Value | — | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.85, up 0.6% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong analyst support, a 52.63% buy rating, and a solid dividend yield. Revenue grew to $37.10B in 2025, though net income margin dipped slightly to 20.99%.
Outlook is positive with earnings growth and strategic acquisitions like MapleMark Bank driving upside. Risks include economic sensitivity and competitive pressures. Wall Street sentiment leans bullish, but investors should monitor credit conditions and interest rate impacts on banking performance.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
